Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Gilead Sciences, Inc. (NASDAQ: GILD) was $64.92 for the day, down -0.82% from the previous closing price of $65.46. In other words, the price has decreased by -$0.82 from its previous closing price. On the day, 5.09 million shares were traded. GILD stock price reached its highest trading level at $65.58 during the session, while it also had its lowest trading level at $64.76.
Ratios:
Our analysis of GILD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.91. For the most recent quarter (mrq), Quick Ratio is recorded 0.72 and its Current Ratio is at 0.98. In the meantime, Its Debt-to-Equity ratio is 1.47 whereas as Long-Term Debt/Eq ratio is at 1.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on May 01, 2024, Reiterated its Buy rating but revised its target price to $85 from $90 previously.
On April 24, 2024, HSBC Securities Upgraded its rating to Hold which previously was Reduce but kept the price unchanged to $69.
Truist Downgraded its Buy to Hold on February 22, 2024, whereas the target price for the stock was revised from $91 to $82.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 02 ’24 when GILEAD SCIENCES, INC. bought 485,250 shares for $0.76 per share. The transaction valued at 368,790 led to the insider holds 7,345,473 shares of the business.
Parsey Merdad sold 2,000 shares of GILD for $145,920 on Apr 01 ’24. The Chief Medical Officer now owns 96,304 shares after completing the transaction at $72.96 per share. On Feb 29 ’24, another insider, Parsey Merdad, who serves as the Chief Medical Officer of the company, sold 8,230 shares for $72.74 each. As a result, the insider received 598,624 and left with 92,706 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GILD now has a Market Capitalization of 80953286656 and an Enterprise Value of 102667157504. As of this moment, Gilead’s Price-to-Earnings (P/E) ratio for their current fiscal year is 180.99, and their Forward P/E ratio for the next fiscal year is 9.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 33.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.95 while its Price-to-Book (P/B) ratio in mrq is 4.63. Its current Enterprise Value per Revenue stands at 3.74 whereas that against EBITDA is 8.04.
Stock Price History:
Over the past 52 weeks, GILD has reached a high of $87.86, while it has fallen to a 52-week low of $64.33. The 50-Day Moving Average of the stock is -7.58%, while the 200-Day Moving Average is calculated to be -14.47%.
Shares Statistics:
GILD traded an average of 7.32M shares per day over the past three months and 8642880 shares per day over the past ten days. A total of 1.25B shares are outstanding, with a floating share count of 1.25B. Insiders hold about 0.10% of the company’s shares, while institutions hold 85.65% stake in the company. Shares short for GILD as of 1713139200 were 21182130 with a Short Ratio of 2.90, compared to 1710460800 on 19247863. Therefore, it implies a Short% of Shares Outstanding of 21182130 and a Short% of Float of 1.7000000000000002.
Dividends & Splits
With its trailing 12-month dividend rate of 3.02, GILD has a forward annual dividend rate of 3.02. Against a Trailing Annual Dividend Yield of 0.046135046The stock’s 5-year Average Dividend Yield is 4.0.
